Group items tagged

The General Pharmaceutical Council (GPhC) has published a new strategy pledging to deliver equality, improve diversity and foster inclusion in all aspects of its work. The strategy was updated after a public consultation held between April and July. It's key themes are: To make regulatory decisions that are demonstrably fair, lawful, and free from discrimination and bias. To use our standards to proactively help tackle discrimination and to make sure everyone can access person-centred care, fostering equality of health outcomes.To lead by example and demonstrate best practice within our organisation, holding ourselves to the same high standards we expect of others. GPhC chair Nigel Clarke said having a strategy is vital as the pandemic has exposed "the scope and scale of inequities in society, in healthcare outcomes and in pharmacy." "Inequality and exclusion are bad for people's health. Therefore, this strategy is fundamental to our core purpose as a regulator and our vision for safe and effective pharmacy care at the heart of healthier communities."

The Royal Pharmaceutical Society (RPS) England director, Ravi Sharma, has resigned after four years on the job. He will be leaving the RPS in October to join Luton and Dunstable University Hospital, part of the Bedfordshire Hospitals NHS Foundation Trust group, as head of pharmacy. RPS will be commencing the recruitment of a new director for England shortly and in the interim Ravi will be working with Paul Bennett, the RPS CEO, to help in delivery of key objectives and in the appointment of his successor. Paul commented: "Ravi has made a significant contribution to the organisation during his time with us. His drive and enthusiasm for advancing the recognition of the role of the Society itself and of pharmacists and professional practice is probably best reflected by his desire to ensure a real focus on personalised medicines and his work on equality and diversity, workforce wellbeing, and most recently the development of a new vision for pharmacy in England.

The International Pharmaceutical Federation (FIP) has issued a new policy statement which encourages a "life-course" approach to vaccination by pharmacists. In the statement, published on September 27, FIP backed expansion of vaccine schedules and strategies so that patients of all age groups could be vaccinated throughout their entire lifespan, from infancy to old age. A life-course approach in public health and healthcare focuses on an individual's health and well-being, including vaccination, administered throughout their entire lifespan, from infancy to old age. FIP urged governments and policymakers to eliminate regulatory barriers, enabling pharmacists to prescribe and administer all relevant vaccines throughout the life-course. Additionally, FIP recommended that policymakers develop remuneration models for pharmacies to deliver sustainable life-course vaccination services within the private and public sectors.

Boehringer Ingelheim's UK & Ireland managing director Uday Bose has been elected chair of the European Medicines Group (EMG). Established in 2001, the EMG is a voice for UK operations of continental European headquartered research-based pharmaceutical companies and seeks to promote a dialogue between the UK Government, the NHS and wider stakeholders. "I am delighted to share the news that I have been elected chair," Bose wrote in a LinkedIn post, adding: "I look forward to working with the EMG to help support the ambition set out in the Life Sciences Vision for the UK to be a world leader in life sciences." Bose is a vastly experienced pharmaceutical industry leader who has had over 20 years' experience spanning general management, health economics, sales and marketing roles with national, regional and global accountability.

At their recent online briefing, DAUK's GP committee outlined a comprehensive 10-point plan designed to relieve pressure on GPs, improve access, reduce mortality rates, lower hospital admissions, and enhance patient satisfaction. DAUK's manifesto advocates reallocating resources, including the Additional Roles Reimbursement Scheme (ARRS), currently directed towards Pharmacy First and acute care hub pilots, amounting to £2 billion. This strategic reallocation aims to enhance primary care capacity and reduce reliance on acute services. Dr Lizzie Toberty, DAUK's GP lead, emphasised the critical need for patients to have timely access to GPs who understand their needs, stating, "We need patients to be able to see a GP who knows them and understands their needs in a timely way wherever possible." She highlighted DAUK's vision to restore general practice as the cornerstone of the NHS through practical, achievable solutions.

The UK government on Thursday (8 May) launched a new plan to tackle antimicrobial resistance (AMR), a global issue that makes infections difficult or impossible to treat. This is the second phase of a series of 5-year national action plans, aimed at supporting the government's 20-year vision to contain and control AMR by 2040. With the launch of this new national action plan, the UK commits to reducing its use of antimicrobials - such as antibiotics, antifungals and antivirals - in humans and animals. Additionally, it aims to strengthen surveillance of drug-resistant infections before they emerge and incentivise industry to develop the next generation of treatments. There are also plans to expand initiatives such as the world-first 'subscription model' for antimicrobials, launched in 2019 as a pilot.

The National Institute for Health and Care Excellence (NICE) has released conclusive draft guidance, suggesting Pfizer's Vydura (rimegepant) as a choice for treating acute migraines in adults with or without aura. However, there is a caveat. This recommendation applies exclusively to individuals with a prior history of migraines, meeting one of the following criteria: At least 2 triptans were tried and they did not work well enough or Triptans were contraindicated or not tolerated, and nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol were tried but did not work well enough. This drug was developed by the US-based Biohaven Pharmaceuticals, acquired by Pfizer in 2022, in an $11.6 billion deal. Nurtec ODT is the commercial name for the drug in the US, while the European Union approved the drug under the name Vydura in April 2022. NICE recommended rimegepant, an oral lyophilisate (dissolving wafer) and the first oral calcitonin gene-related peptide (CGRP) receptor antagonist for acute migraine treatment, to be taken at the onset of a migraine attack. Migraine affects one in seven people in the UK, often with a debilitating impact, Pfizer UK said in a statement. The condition entails symptoms such as head pain, vomiting, nausea, altered vision, fatigue, and heightened sensitivity to light, sound, and odours.

The Department of Health and Social Care (DHSC) has created a new NIHR Research Delivery Network (RDN) to support the successful delivery of health and social care research in England. The network, which will start operating from next year, will play a critical and active role in implementing government policies. It will support in implementing the Life Sciences Vision, the Future of UK Clinical Research Delivery vision, and policy for life sciences research and development. The new network would be mainly working on growing the amount of commercial clinical research as its key strategic ambition. Also, NIHR RDN will be responding to the findings of the Lord O'Shaughnessy review, which set out a clear blueprint for how the UK can return to its global leadership role.

Walgreens Boots Alliance, Boots UK's parent company, has appointed Tim Wentforth as its new CEO, effective on 23 October. He joined WBA at a pivotal time when the company plans to downsize the business while driving execution and creating greater value for employees, patients, customers and shareholders. Wentforth replaced Rosalind Brewer, who stepped down on 1 September, after two years at the helm. He joined from Evernorth, Cigna's health services organisation based in Connecticut, where he served as its founding CEO. Prior to Cigna, he also held top roles in companies including specialty pharmacy company Accredo and pharmacy benefit manager Express Scripts.

Ceuta Group, a global brand building business providing end-to-end outsourcing services in the health and wellness industry has appointed David Wright as a non-executive board director. With extensive experience of leading global consumer healthcare companies, David joins Ceuta Group following five years as CEO/President of global pharmaceutical company, HRA Pharma and six years as Global Head of Boehringer Ingelheim's consumer business. During his time at HRA Pharma and Boehringer Ingelheim GmBH, David led both companies through substantial organisational and strategy re-design which led to sustainable growth and profitability. The company said: "David has a strong belief that combining the right structure, operational priorities and processes, with a strong focus on company culture, are critical factors in building successful businesses. This approach saw him lead a period of transformation at HRA Pharma resulting in the company's successful acquisition by Perrigo Company plc." David will take an active role on the Ceuta Group Board supporting and building the company's strategic vision and priorities. He will also help shape the company's growth plans on an operational level to ensure Ceuta Group continues to meet client's needs today and into the future.

Glenmark, a multinational pharmaceutical company, has partnered with AI data-driven supply chain management platform 7bridges. Initially focusing on their European business, where they have operations in 15 markets, the supply chain and logistics function is a big focus area for this cost reduction. The partnership with 7bridges will allow Glenmark to baseline their supply chain data giving them visibility of data, cost and service performance across their network of logistics service providers. This exercise will identify areas where invoices from their logistics service providers are being incorrectly or overcharged. With automatic dispute raising, savings will be quickly achieved. The platform will then enable Glenmark to benchmark their data, so they can compare the performance and cost of their LSPs to the wider industry. With Glenmark's global vision to emerge as a leading integrated research-based global pharmaceutical company, this investment in their supply chain will be integral to achieving this. The next step in the partnership will be to run simulations to optimise road freight services and 3PL operations, with the aim to then roll out globally.

The 'Life and Health Sciences Launchpad' has been introduced to focus on the precision medicine sector. It would help businesses and researchers to level up their impact on economic growth within the region. The launchpad has been funded by Innovate UK, part of UK Research and Innovation (UKRI). Kerry Curran, Director of GB & EU Trade in the Department for the Economy hailed the decision to support NI's "trailblazing" sector. She said: "Life and Health Science, including our highly innovative precision medicine cluster, is an area the Department is also prioritising through its 10X Economy Vision, and this Launchpad represents a further endorsement of the world-leading growth potential of precision medicine, and indeed life and health science, in Northern Ireland.

AmerisourceBergen, a leading pharmaceutical solutions organisation announced its intent to change its name to 'Cencora' to better reflect its bold vision and purpose-driven approach to creating healthier futures. Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen said: "Over time, we have established ourselves as a trusted industry partner that prioritizes innovation, advocates for patient access and advances strategic partnerships across the global pharmaceutical supply chain. To further bolster our position, we must continue to adapt and evolve within our dynamic industry as we pursue the goal of enhancing health outcomes. Building a unified brand is fundamental to our identity as a global healthcare company. We believe our new name better reflects who we are today and our impact across pharmaceutical care." AmerisourceBergen intends to begin operating as Cencora in the second half of calendar year 2023. The change to Cencora is aligned with the organisation's growth strategy and continued emphasis on innovation. AmerisourceBergen has focused on supporting pharmaceutical advancement and access for patients, manufacturers, and providers across the global healthcare supply chain.

At the Future of Britain Conference 2024, the newly appointed Secretary of Health and Social Care, (DHSC) Wes Streeting, stated that "Labour's DNA is in the NHS". He also called for a long-term approach to reform the broken health sector and the integration of artificial intelligence (AI) to steer the healthcare system towards sustainability and growth. Hosted by Tony Blair Institute for Global Change and My Life My Say today, Tuesday, 9, Streeting discussed the plans to fix the healthcare system and role of Artificial Intelligence (AI) in "making the right choices" by bringing in three essential shifts in the healthcare. Criticising the previous Conservative administration for leaving "massive burning deck issues" due to constant reshuffling within the Department of Health and Social Care (DHSC), Streeting lamented that this "instability" and "indecisions" have made comprehensive reform even more pressing. Drawing inspiration from Chancellor Rachel Reeves' speech on economic growth, Streeting stressed the interconnectedness of health and economic prosperity.

A new Attention-Deficit-Hyperactive disorder (ADHD) taskforce has been launched by National Health Services England (NHSE) to counter the challenges faced by many suffering from the neurodevelopmental condition. The ADHD taskforce aligns with the NHS Long Term Plan's vision to revolutionise mental health services, with a specific emphasis on bolstering community-based care and reducing reliance on inpatient services. The NHS has partnered with the government to tackle the escalating demands including increasing funding, improving system efficiency, altering the service provision model, and clinical prioritisation by bringing together expertise from across a broad range of sectors, including the NHS, education and justice, to help provide a joined-up approach in response to concerns around rising demand. Over the past two decades, there has been a significant expansion in the acknowledgement and successful medical interventions for ADHD, leading to a steady rise in clinical requests throughout the UK.

Matthew Taylor, Chief Executive of the NHS Confederation, delivered a compelling speech at the NHS ConfedExpo 2024, emphasising the critical need for investment in community-based care and the revitalisation of primary care services. In his address, Taylor also criticised the current health policy as "not fit for purpose," calling for radical changes to shift the NHS from a reactive to a proactive health model. Addressing delegates at the Manchester event, Taylor highlighted the importance of shifting resources towards prevention and community services. Underscoring a strategic pivot from reactive to proactive health models, he said: "We must see action to fulfil the long-held vision of a health service that invests better upstream in prevention, in primary and in community-based care."

Wes Streeting MP has been appointed Secretary of State for Health and Social Care in the new Labour Government. The Ilford North MP will now take on the critical role of overseeing the National Health Service (NHS) and implementing Labour's ambitious health agenda. At the core of the Labour Party's healthcare reform manifesto is enhancing accessibility to primary and community healthcare. This involves implementing a 'Community Pharmacist Prescribing Service,' to empower pharmacists with independent prescribing rights where clinically suitable. This initiative aims to alleviate the strain on GP practices and enhance service accessibility. Additionally, the manifesto proposes piloting Neighbourhood Health Centres, to integrate various healthcare services -such as family doctors, district nurses, and mental health specialists under one roof.